{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:24Z","timestamp":1786987524288,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cpcardiol.2022.101536","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:16:29Z","timestamp":1670249789000},"page":"101536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Yi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101536_bib0001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction\u2013Alzheimer's disease of the heart?","volume":"368","author":"Willis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0004","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0006","first-page":"378","article-title":"Causes of late mortality with dual antiplatelet therapy after coronary stents","volume":"37","author":"Mauri","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2018.09.014","article-title":"Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects","volume":"838","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0008","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/01.hjh.0000746052.91980.73","article-title":"Multiple myeloma patients undergoing carfilzomib: validation of a management protocol for cardiovascular risk assessment and a new score for events prediction","volume":"39","author":"Astarita","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0009","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0010","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0011","article-title":"Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study","author":"Al-Yafeai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0012","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0013","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2017.1393674","article-title":"Cardio-oncology in multiple myeloma: is it time for a specific focus?","volume":"59","author":"Mancuso","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0014","doi-asserted-by":"crossref","first-page":"134","DOI":"10.37616\/2212-5043.1311","article-title":"Carfilzomib-induced Cardiotoxicity: an analysis of the FDA adverse event reporting system (FAERS)","volume":"34","author":"Buck","year":"2022","journal-title":"J Saudi Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0016","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/10428194.2022.2038373","article-title":"Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed\/refractory multiple myeloma","volume":"63","author":"Muramatsu","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0017","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/eurheartj\/ehab724.3416","article-title":"Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressure","volume":"42","author":"Efentakis","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0018","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0019","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0020","first-page":"622","article-title":"Flow-mediated dilatation (FMD) and aortic blood pressure may predict cardiovascular adverse events during carfilzomib therapy: a prospective study in relapsed\/refractory multiple myeloma patients","volume":"11","author":"Kastritis","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0021","first-page":"4","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0022","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221104584","article-title":"Real-world effectiveness and safety analysis of carfilzomib\u2013lenalidomide\u2013dexamethasone and carfilzomib\u2013dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis","volume":"13","author":"Onda","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ajh.25435","article-title":"Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma","volume":"94","author":"Forsberg","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.13900","article-title":"A phase 1\/2 study of carfilzomib in Japanese patients with relapsed and\/or refractory multiple myeloma","volume":"172","author":"Watanabe","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0026","first-page":"11","article-title":"Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy","author":"Bruno","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature","volume":"128","author":"Bockorny","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0028","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/eurheartj\/ehab724.2854","article-title":"Aortic hemodynamic parameters as predictors of incident or deteriorating hypertension during carfilzomib therapy in patients with relapsed multiple myeloma","volume":"42","author":"Laina","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0029","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the International cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (endeavor): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0032","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_107_20","article-title":"Severe right-sided heart failure and pulmonary hypertension with carfilzomib treatment in multiple myeloma","volume":"21","author":"Mathur","year":"2020","journal-title":"Heart Views"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0033","article-title":"Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report","volume":"9","author":"McGregor","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0034","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cvr\/cvw047","article-title":"Carfilzomib reverses pulmonary arterial hypertension","volume":"110","author":"Wang","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0035","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0735-1097(20)31350-4","article-title":"Cardiovascular outcomes following bortezomib reinitiation after congestive heart failure diagnosis in multiple myeloma","volume":"75","author":"Restrepo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0036","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0038","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0039","first-page":"S113","article-title":"Cardiotoxicity of bortezomib - the anticancer therapeutic agent","volume":"9","author":"Bil","year":"2010","journal-title":"Eur J Heart Fail, Suppl."},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0040","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0041","first-page":"437","article-title":"Detection and monitoring of cardiotoxicity-what does modern cardiology offer?","volume":"16","author":"Jurcut","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.645678","article-title":"Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients","volume":"8","author":"Mingrone","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.004661","article-title":"Additive prognostic value of left ventricular systolic dysfunction in a population-based cohort","volume":"9","author":"Kuznetsova","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0044","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.echo.2015.02.006","article-title":"Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients","volume":"28","author":"Rhea","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0046","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0047","first-page":"961","article-title":"Cardiotoxicity associated with bortezomib: a single-center experience","volume":"13","author":"Gurram","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0048","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.clml.2019.09.418","article-title":"KD-PACE salvage therapy for aggressive relapsed multiple myeloma","volume":"19","author":"Harrell","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0049","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488610789869111","article-title":"Antineoplastic chemotherapy induced QTc prolongation","volume":"5","author":"Bagnes","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0051","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1592\/phco.30.7.684","article-title":"Drug-induced QT-interval prolongation: considerations for clinicians","volume":"30","author":"Li","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0052","first-page":"865","volume":"11","author":"Gevaert","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0053","first-page":"6","article-title":"Upregulation of proteasome activity rescues cardiomyocytes following pulse treatment with a proteasome inhibitor","volume":"4","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0054","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/HCO.0b013e32834598fe","article-title":"The ubiquitin-proteasome system in cardiomyopathies","volume":"26","author":"Schlossarek","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/eurjhf\/hft034","article-title":"Primary proteasome inhibition results in cardiac dysfunction","volume":"15","author":"Herrmann","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0056","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCRESAHA.112.270983","article-title":"Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice","volume":"111","author":"Tian","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0057","first-page":"384","article-title":"Cardiovascular effects of carfilzomib, a new proteasome inhibitor, on coronary artery resistance, vascular tone and vascular reactivity","volume":"134","author":"Scarabelli","year":"2016","journal-title":"Cardiology (Switzerland)"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0058","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/cncr.33647","article-title":"Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1\/2 study of the European Myeloma Network","volume":"127","author":"Gay","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0059","first-page":"229","article-title":"The phase I\/II trial EMN09: carfilzomib, bendamustine, and dexamethasone (KBd) is effective and well tolerated in advanced multiple myeloma","volume":"41","author":"Gramatzki","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0060","first-page":"130","article-title":"Efficacy and safety of long-term ixazomib maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) not undergoing transplant: an integrated analysis of four phase 1\/2 studies","author":"Dimopoulos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0061","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V126.23.4265.4265","article-title":"Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at memorial sloan kettering cancer center","volume":"126","author":"Land","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0062","first-page":"37","article-title":"Proteasome inhibitor associated cardiovascular adverse events: a real-world claims based study","author":"Waxman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0063","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0064","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0066","first-page":"947","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0067","doi-asserted-by":"crossref","first-page":"D370","DOI":"10.1093\/eurheartj\/sux019","article-title":"ANMCO\/AIOM\/AICO consensus document on clinical and management pathways of cardio-oncology: executive summary","volume":"19","author":"Tarantini","year":"2017","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0068","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0069","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0071","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0072","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0073","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00277-018-3238-4","article-title":"Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma","volume":"97","author":"Chen","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0074","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0075","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0076","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0077","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0078","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0079","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0081","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0082","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0083","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0084","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCRESAHA.112.300521","article-title":"Role of the ubiquitin proteasome system in the heart","volume":"112","author":"Pagan","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0086","doi-asserted-by":"crossref","first-page":"21652","DOI":"10.1074\/jbc.M602105200","article-title":"Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function","volume":"281","author":"Wei","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0087","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.0000232501.08576.73","article-title":"Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis","volume":"26","author":"Versari","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0088","first-page":"130","article-title":"Comparison of proteasome inhibitors-induced cardiotoxicity (carfilzomib vs. bortezomib): insights into the molecular mechanisms","author":"Efentakis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0089","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-136916","article-title":"Carfilzomib-induced hypertension is mediated by ion channel dysregulation in the kidneys; the potent role of AMP-activated kinase \u03b1","volume":"136","author":"Efentakis","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0091","first-page":"580","article-title":"Carfilzomib-induced cardiotoxicity: molecular mechanisms and the emerging role of metformin as a prophylactic therapy","volume":"2","author":"Kremastiotis","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0092","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0093","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0094","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0095","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0096","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0097","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","article-title":"Management of carfilzomib-associated cardiac adverse events","volume":"16","author":"Mikhael","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0098","first-page":"87","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0099","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41408-017-0026-7","article-title":"Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma","volume":"7","author":"Jain","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.redox.2017.02.006","article-title":"Reciprocal regulation of eNOS, H(2)S and CO-synthesizing enzymes in human atheroma: correlation with plaque stability and effects of simvastatin","volume":"12","author":"Sigala","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0101","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/db12-0533","article-title":"Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes","volume":"62","author":"He","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0102","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yjmcc.2014.09.029","article-title":"The role of autophagic degradation in the heart","volume":"78","author":"Nishida","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0104","first-page":"132","article-title":"Metformin restores AMPK alpha-mediated autophagy and prevents carfilzomib-induced cardiotoxicity in vivo","author":"Kremastiotis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pros.24443","article-title":"Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: a population-based study","volume":"83","author":"Lee","year":"2022","journal-title":"The Prostate"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0106","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2019.09.422","article-title":"Angiotensin II receptor blockers might reduce a cardiotoxicity induced by carfilzomib: retrospective analysis of 17 cases","volume":"19","author":"Fukuta","year":"2019","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0107","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/15376516.2016.1236425","article-title":"Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-\u03baB and MAPK signaling in rats","volume":"26","author":"Imam","year":"2016","journal-title":"Toxicol Mech Methods"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0108","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20090557","article-title":"Role of nuclear factor kappaB in cardiovascular health and disease","volume":"118","author":"Van der Heiden","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-kappa B, hypertrophic gene expression and oxidative stress","volume":"17","author":"Imam","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cpcardiol.2022.101536_bib0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/15376516.2016.1143071","article-title":"Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats","volume":"26","author":"Al-Harbi","year":"2016","journal-title":"Toxicol Mech Methods"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:35Z","timestamp":1758938375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622004339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0146280622004339"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101536","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101536"}}